Intravenous ferric carboxymaltose is effective and safe for the treatment of iron deficiency anaemia in children affected by inflammatory bowel disease

Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review

“…The patient groups included 10 studies on children with ID/IDA associated with different underlying conditions [ 23 , 24 , 28 , 30 , 33 , 35 , 36 , 39 , 52 , 53 ]; in three of these, all the children were under 14 years of age [ 23 , 28 , 39 ]. There were also eight studies (including the audit and two prospective studies) on children with inflammatory bowel disease (IBD) [ 22 , 27 , 29 , 31 , 34 , 40 , 41 , 51 ] and two studies on children with varying gastrointestinal disorders [ 32 , 37 ]. Other patient groups included in the studies were restless legs syndrome (one study [ 25 ]), restless sleep disorder (one study [ 26 ]), heart failure (one study [ 38 ]) and intestinal failure (one study in children under 2 years of age [ 21 ]).…”

“…Of these, 33 were related to the use of FCM in children or adolescents < 18 years and were included in this narrative review (Table 1). The 33 publications evaluated in this analysis consisted of 19 retrospective studies [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39], two prospective studies [40,41], eight case reports [42][43][44][45][46][47][48][49], one case series (included three case reports [50]), one audit [51], one pharmacokinetic/pharmacodynamic modelling study [52] and one letter to the editor [53].…”